CHRO stock is currently trading at $0.76, reflecting a 13.09% premarket increase following the announcement of an expanded share repurchase program and an extension of its termination date to June 30, 2025. Bulls view this positively as it signals management's confidence in the company's valuation and potential for shareholder value creation. However, the lack of revenue and consistent negative earnings (-$0.55 in Q1 2024, -$0.31 in Q2 2024) may limit upside momentum.